Volume spike seen in Nokia Corporation (NYSE:NOK), Zogenix Inc (NASDAQ:ZGNX)

Posted by Michael Korte May 16, 2013 0 Comment 1241 views


Miami, FL 05/16/2013 (GDPInsider) – Nokia Corporation (NYSE:NOK): The trading session on Wednesday saw Nokia Corporation (NYSE:NOK) climbing up by 3.02%. It opened at a price of $3.68 which touched an intraday high of $3.77, before moving down to close at $3.75 per share. Around 51.41 million shares traded hands in the previous trading session, which stood below the average volume of 37.06 million that was measured over a 30-day period.

The Nokia Corporation CEO, Elop has indicated that the company is considering developing 7-nch Android tablets. However, he also said that he favored the Windows operating system. NOK has recently launched the Nokia Lumia 925. The smartphone manufacturer spotlighted that its flagship smartphone is outfitted with highly-advanced, next generation imaging software and lens technology. It is able to capture sharper and clearer videos and pictures as well as the best low light images.

NOK has three different operating segments: NAVTEQ, Devices & Services and Nokia Siemens Networks. The Devices & Services segment is responsible for the development and management of the portfolio of mobile products that the company has. It also designs and develops applications and content.

How Should Investors Trade NOK Now? Get the latest trends and data here.

Zogenix Inc (NASDAQ:ZGNX): The trading session on Wednesday saw climbing down by 3.64%. It opened at a price of $1.64 which was also the intraday high, before moving down to close at $1.59 per share. Around 3.28 million shares traded hands in the previous trading session, which stood above the average volume of 0.619 million that was measured over 30 days.

Insider-trading activity, especially when the stock is bullish, is the most handy when the company such as ZGNX has experienced transactions over the past six months. Zogenix, Inc. (NASDAQ:ZGNX) has seen 4 distinct unique insiders-buying, and it has had zero insider sales

ZGNX is a pharma company that commercializes and develops products that are used in the treatment of pain and central nervous system disorders. Sumavel DosePro, the company’s product offers subcutaneous administration of sumatriptan, without a needle. It is used in the treatment of cluster headache and migraine and is available in a single-use, pre-filled delivery system.

Is ZGNX a solid investment at these levels? Get valuable updates and exclusive insights here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Michael Korte

Michael Korte an investigative reporter at GDP Insider and is a breaking news reporter. Michael work includes investigations of misconduct by federal prosecutors and industrial air pollution around the nation's schools. His reporting has been recognized with the Hillman Prize for Newspaper Journalism, the Grantham Prize for Excellence in Reporting on the Environment, and the Philip Meyer Journalism Award for reporting that incorporates social science methods.

View all post by Michael Korte Visit author's website

Write Your Comment